Abstract Library

#1319 Neuroendocrine Cancer Patient Experience Survey

Introduction: Annually a national patient cancer survey (NCPES) is performed to assess perceived patient care. It was noted that in the previous cancer experience surveys patients with NET had not been invited to participate. The NET Patient Foundation (NETPF) commissioned Quality Health to undertake this survey in patients with a known diagnosis of neuroendocrine cancer. The patients were identified via NET centres of excellence around England.

Conference: 13th Annual ENETSConcerence (2016)

Presenting Author: Srirajaskanthan R

Authors: Bouvier C, Sissons M, Srirajaskanthan R,

Keywords: Diagnosis and referral, communication, information, explanation, treatment, CNS, support,

#1163 Mitotane, Adrenolitic Drug, Inhibits Cell Survival and Function of Several Pituitary Cytotypes

Introduction: Mitotane (DDD) is an adrenolytic agent that is used for the treatment of adrenocortical carcinoma. We previously demonstrated that DDD affects thyrotrope cell viability and function. These data represent a possible explanation of the biochemical picture consistent with central hypothyroidism in patients undergoing DDD therapy. DDD also inhibits corticotrope cell viability by inducing caspase-mediated apoptosis and reduces POMC expression as well as basal and CRH-induced ACTH secretion. Cells originating from tissues different from pituitary are not sensitive to the inhibitory effects of DDD. Our data suggest that DDD inhibits cell survival and function of many pituitary cytotypes, acting with a generalized, but specific, toxic effect. The majority of male patients undergoing adjuvant DDD therapy show a clinical picture of hypogonadism, characterized by low free testosterone and unmodified LH concentration

Conference: 12th Annual ENETSConcerence (2015)

Presenting Author: Gentilin E

Authors: Gentilin E, Gagliano T, Benfini K, Di Pasquale C, Falletta S,

Keywords: mitotane, adrenocortical cancer, pituitary,

#492 Should Primary Hyperparathyroidism at Age Below 40 Years Always Lead to Search for MEN-1, Despite Presence of Other Plausible Explanations?

Introduction: A 30-year-old female patient with inherited osteogenesis imperfecta (OI) Type 1 was referred due to hypercalcaemia and suspicion of primary hyperparathyroidism (pHPT). She had serum ca2+ 1.56 mmol/L, serum parathyroid hormone 115 ng/ml (< 70), and pHPT was diagnosed, but no scan uptake. By exploratory neck surgery, all parathyroid glands were hyperplastic and 3 ½ parathyroid + thymus were removed. The HPT was hypothesised to be due to abnormal calcium metabolism from OI (J Endocrinol Invest 1999), although not described previously.

Conference: 9th Annual ENETSConcerence (2012)

Presenting Author:

Authors: Feldt-Rasmussen U, Rasmussen �, Friis-Hansen L,

Keywords: MEN-1, screening, pHPT,